Edition:
United Kingdom

Tigenix NV (TIG.OQ)

TIG.OQ on NASDAQ Stock Exchange Global Select Market

41.04USD
22 Jun 2018
Change (% chg)

$-0.41 (-0.99%)
Prev Close
$41.45
Open
$41.41
Day's High
$41.41
Day's Low
$40.95
Volume
3,236
Avg. Vol
543
52-wk High
$43.94
52-wk Low
$19.24

Chart for

About

TiGenix NV is a Belgium-based biopharmaceutical company focused on the development and commercialization of therapeutics from its platforms of allogeneic, or donor-derived, expanded stem cells. The Company's two products from the adipose-derived stem cell platform are in clinical development. Cx601 is in Phase III for the... (more)

Overall

Beta: -0.68
Market Cap(Mil.): €282.48
Shares Outstanding(Mil.): 266.49
Dividend: --
Yield (%): --

Financials

  TIG.OQ Industry Sector
P/E (TTM): -- 82.81 32.74
EPS (TTM): -0.04 -- --
ROI: -18.81 2.00 14.38
ROE: -32.21 3.49 16.08

BRIEF-Takeda Says Announces Voluntary And Conditional Public Takeover Bid For Outstanding Shares,Warrants And American Depositary Shares Of Tigenix NV To Commence April 30, 2018

* SAYS ANNOUNCES VOLUNTARY AND CONDITIONAL PUBLIC TAKEOVER BID FOR OUTSTANDING SHARES, WARRANTS AND AMERICAN DEPOSITARY SHARES OF TIGENIX NV TO COMMENCE APRIL 30, 2018 Source text for Eikon: Further company coverage: (Reporting By Chris Gallagher)

25 Apr 2018

BRIEF-Tigenix FY Operating Loss Widens to 53.2 Million Euros

* FY OPERATING LOSS OF EUR 53.2 MILLION VERSUS LOSS OF EUR 3.0 MILLION YEAR AGO

12 Apr 2018

BRIEF-Tigenix And Takeda Announce Alofisel® (Darvadstrocel) Receives Approval To Treat Complex Perianal Fistulas In Crohn's Disease In Europe

* TIGENIX AND TAKEDA ANNOUNCE ALOFISEL® (DARVADSTROCEL) RECEIVES APPROVAL TO TREAT COMPLEX PERIANAL FISTULAS IN CROHN'S DISEASE IN EUROPE

23 Mar 2018

Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion

PARIS French healthcare group Sanofi has agreed to buy U.S. haemophilia specialist Bioverativ for $11.6 billion(8.34 billion pounds), its biggest deal for seven years and a major play to strengthen its presence in treatments for rare diseases. | Video

22 Jan 2018

BRIEF-Tigenix Says Received Transparency Notification From Jpmorgan Chase & Co​ On Jan 16

* ‍TRANSPARENCY NOTIFICATION PURSUANT TO ARTICLE 14 OF LAW OF MAY 2, 2007​‍

18 Jan 2018

$11 billion biotech binge fuels forecasts of 2018 M&A surge

LONDON An $11 billion (8.12 billion pounds) burst of biotech bids in just four days has fuelled expectations of a 2018 surge in life science deals as large drugmakers shop for promising assets from smaller rivals.

08 Jan 2018

$11 billion biotech binge fuels forecasts of 2018 M&A surge

LONDON An $11 billion burst of biotech bids in just four days has fueled expectations of a 2018 surge in life science deals as large drugmakers shop for promising assets from smaller rivals.

08 Jan 2018

Japan's Takeda to acquire TiGenix for $630 mln

TOKYO, Jan 5 Japan's Takeda Pharmaceutical Co said on Friday it has agreed to buy Belgian biotech group TiGenix NV for 520 million euros ($628 million).

05 Jan 2018

Earnings vs. Estimates